Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
NCT02307643
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
17
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG:
MT-1303 Low dose
DRUG:
MT-1303 High dose
Sponsor
Tanabe Pharma Corporation